ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) and Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) announce they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. The transaction, which values Alimera at approximately $381 million in up front consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024. Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with maintaining better vision longer.
Read the full article: ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences //
Source: https://www.globenewswire.com/news-release/2024/06/24/2902835/0/en/ANI-Pharmaceuticals-to-Further-Expand-Rare-Disease-Business-through-Acquisition-of-Alimera-Sciences.html